The EDGE

HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?

H S Hochster

Br J Cancer 2013 108: 477-478; 10.1038/bjc.2013.20

Minireview

Cancer heterogeneity: implications for targeted therapeutics

R Fisher, L Pusztai and C Swanton

Br J Cancer 2013 108: 479-485; advance online publication, January 8, 2013; 10.1038/bjc.2012.581

Marine polyunsaturated fatty acids and cancer therapy

V C Vaughan, M-R Hassing and P A Lewandowski

Br J Cancer 2013 108: 486-492; advance online publication, January 8, 2013; 10.1038/bjc.2012.586

Clinical Studies

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

D Cunningham, R P W Wong, G D'Haens, J-Y Douillard, J Robertson, A M Stone and E Van Cutsem on behalf of the HORIZON I study group

Br J Cancer 2013 108: 493-502; advance online publication, January 8, 2013; 10.1038/bjc.2012.545

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

M Peeters, A H Strickland, M Lichinitser, A V S Suresh, G Manikhas, J Shapiro, W Rogowski, X Huang, B Wu, D Warner, R Jain and N C Tebbutt

Br J Cancer 2013 108: 503-511; advance online publication, January 29, 2013; 10.1038/bjc.2012.594

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas

K P Raj, J A Zell, C L Rock, C E McLaren, C Zoumas-Morse, E W Gerner and F L Meyskens

Br J Cancer 2013 108: 512-518; advance online publication, January 22, 2013; 10.1038/bjc.2013.15

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer

S Lorenzen, C Pauligk, N Homann, H Schmalenberg, E Jäger and S-E Al-Batran

Br J Cancer 2013 108: 519-526; advance online publication, January 15, 2013; 10.1038/bjc.2012.588

Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature

D M Mistrangelo, M Bellò, P Cassoni, E Milanesi, P Racca, F Munoz, G Fora, N Rondi, N Gilbo, R Senetta, U Ricardi and M Morino

Br J Cancer 2013 108: 527-532; advance online publication, January 17, 2013; 10.1038/bjc.2012.600

Men’s preferences for prostate cancer screening: a discrete choice experiment

E W de Bekker-Grob, J M Rose, B Donkers, M-L Essink-Bot, C H Bangma and E W Steyerberg

Br J Cancer 2013 108: 533-541; advance online publication, January 29, 2013; 10.1038/bjc.2013.5

Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study

S Taghipour, D Banjevic, A B Miller, N Montgomery, A K S Jardine and B J Harvey

Br J Cancer 2013 108: 542-548; advance online publication, January 15, 2013; 10.1038/bjc.2012.596

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer

N Xenidis, M Perraki, S Apostolaki, S Agelaki, K Kalbakis, N Vardakis, A Kalykaki, A Xyrafas, S Kakolyris, D Mavroudis and V Georgoulias

Br J Cancer 2013 108: 549-556; advance online publication, January 17, 2013; 10.1038/bjc.2012.597

Translational Therapeutics

Regulation of tamoxifen sensitivity by a PAK1–EBP1 signalling pathway in breast cancer

A Ghosh, S Awasthi, J R Peterson and A W Hamburger

Br J Cancer 2013 108: 557-563; advance online publication, January 29, 2013; 10.1038/bjc.2013.11

Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion

K Viola, S Kopf, N Huttary, C Vonach, N Kretschy, M Teichmann, B Giessrigl, I Raab, S Stary, S Krieger, T Keller, S Bauer, B Hantusch, T Szekeres, R de Martin, W Jäger, W Mikulits, H Dolznig, G Krupitza and M Grusch

Br J Cancer 2013 108: 564-569; advance online publication, October 23, 2012; 10.1038/bjc.2012.485

In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen

N Kretschy, M Teichmann, S Kopf, A G Atanasov, P Saiko, C Vonach, K Viola, B Giessrigl, N Huttary, I Raab, S Krieger, W Jäger, T Szekeres, S M Nijman, W Mikulits, V M Dirsch, H Dolznig, M Grusch and G Krupitza

Br J Cancer 2013 108: 570-578; advance online publication, January 8, 2013; 10.1038/bjc.2012.580

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer

F Meng, G Sun, M Zhong, Y Yu and M A Brewer

Br J Cancer 2013 108: 579-586; advance online publication, January 31, 2013; 10.1038/bjc.2013.10

Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus

J C Boer, U M Domanska, H Timmer-Bosscha, I G J Boer, C J C de Haas, J V Joseph, F A E Kruyt, E G E de Vries, W F A den Dunnen, J A G van Strijp and A M E Walenkamp

Br J Cancer 2013 108: 587-596; advance online publication, January 15, 2013; 10.1038/bjc.2012.603

Molecular Diagnostics

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer

N Kachroo, T Valencia, A Y Warren and V J Gnanapragasam

Br J Cancer 2013 108: 597-601; advance online publication, November 20, 2012; 10.1038/bjc.2012.507

Astronomical algorithms for automated analysis of tissue protein expression in breast cancer

H R Ali, M Irwin, L Morris, S-J Dawson, F M Blows, E Provenzano, B Mahler-Araujo, P D Pharoah, N A Walton, J D Brenton and C Caldas

Br J Cancer 2013 108: 602-612; advance online publication, January 17, 2013; 10.1038/bjc.2012.558

Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study

S Y Liao, W H Rodgers, J Kauderer, K M Darcy, R Carter, N Susumu, S Nagao, J L Walker, M Hatae and E J Stanbridge

Br J Cancer 2013 108: 613-620; advance online publication, January 8, 2013; 10.1038/bjc.2012.578

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma

D J Pinato, F A Mauri, T Lloyd, V Vaira, C Casadio, R L Boldorini and R Sharma

Br J Cancer 2013 108: 621-628; advance online publication, January 29, 2013; 10.1038/bjc.2013.9

Detection of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer

Y Hashida, M Imajoh, Y Nemoto, M Kamioka, A Taniguchi, T Taguchi, M Kume, K Orihashi and M Daibata

Br J Cancer 2013 108: 629-637; advance online publication, January 15, 2013; 10.1038/bjc.2012.567

Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue

J H Kauppila, A E Mattila, T J Karttunen and T Salo

Br J Cancer 2013 108: 638-643; advance online publication, January 3, 2013; 10.1038/bjc.2012.589

Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma

N Takeshita, I Hoshino, M Mori, Y Akutsu, N Hanari, Y Yoneyama, N Ikeda, Y Isozaki, T Maruyama, N Akanuma, A Komatsu, M Jitsukawa and H Matsubara

Br J Cancer 2013 108: 644-652; advance online publication, January 29, 2013; 10.1038/bjc.2013.8

MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis

W Wu, M Takanashi, N Borjigin, S-i Ohno, K Fujita, S Hoshino, Y Osaka, A Tsuchida and M Kuroda

Br J Cancer 2013 108: 653-661; advance online publication, January 15, 2013; 10.1038/bjc.2012.587

Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting

J P Tiernan, S L Perry, E T Verghese, N P West, S Yeluri, D G Jayne and T A Hughes

Br J Cancer 2013 108: 662-667; advance online publication, January 15, 2013; 10.1038/bjc.2012.605

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

V Martin, L Landi, F Molinari, G Fountzilas, R Geva, A Riva, P Saletti, S De Dosso, A Spitale, S Tejpar, K T Kalogeras, L Mazzucchelli, M Frattini and F Cappuzzo

Br J Cancer 2013 108: 668-675; advance online publication, January 24, 2013; 10.1038/bjc.2013.4

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer

C P H Vreuls, S W M Olde Damink, G H Koek, A Winstanley, E Wisse, R H E Cloots, M A J van den Broek, C H C Dejong, F T Bosman and A Driessen

Br J Cancer 2013 108: 676-680; advance online publication, January 3, 2013; 10.1038/bjc.2012.590

Epidemiology

Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis

A Downing, A Aravani, U Macleod, S Oliver, P J Finan, J D Thomas, P Quirke, J R Wilkinson and E J A Morris

Br J Cancer 2013 108: 681-685; advance online publication, January 3, 2013; 10.1038/bjc.2012.585

Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers

G Lyratzopoulos, G A Abel, S McPhail, R D Neal and G P Rubin

Br J Cancer 2013 108: 686-690; advance online publication, February 7, 2013; 10.1038/bjc.2013.1

A comprehensive assessment of the impact of errors in the cancer registration process on 1- and 5-year relative survival estimates

M J Rutherford, H Møller and P C Lambert

Br J Cancer 2013 108: 691-698; advance online publication, January 29, 2013; 10.1038/bjc.2013.12

Study populations for period analyses of cancer survival

L Jansen, T Hakulinen and H Brenner

Br J Cancer 2013 108: 699-707; advance online publication, January 29, 2013; 10.1038/bjc.2013.14

Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition

S Rohrmann, J Linseisen, N Allen, H B Bueno-de-Mesquita, N F Johnsen, A Tjønneland, K Overvad, R Kaaks, B Teucher, H Boeing, T Pischon, P Lagiou, A Trichopoulou, D Trichopoulos, D Palli, Vittorio Krogh, R Tumino, F Ricceri, M V Argüelles Suárez, A Agudo, M-J Sánchez, M-D Chirlaque, A Barricarte, N Larrañaga, H Boshuizen, H J van Kranen, P Stattin, M Johansson, A Bjartell, D Ulmert, K-T Khaw, N J Wareham, Pietro Ferrari, I Romieux, M J R Gunter, Elio Riboli and T J Key

Br J Cancer 2013 108: 708-714; advance online publication, November 20, 2012; 10.1038/bjc.2012.520

Use of statins and risk of glioma: a nationwide case–control study in Denmark

D Gaist, L Andersen, J Hallas, H Toft Sørensen, H D Schrøder and S Friis

Br J Cancer 2013 108: 715-720; advance online publication, January 15, 2013; 10.1038/bjc.2012.536

The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study

S J Cotton, J Belcher, P Rose, S K Jagadeesan and R D Neal

Br J Cancer 2013 108: 721-726; advance online publication, January 29, 2013; 10.1038/bjc.2013.13

The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium

A S Felix, L S Cook, M M Gaudet, T E Rohan, L J Schouten, V W Setiawan, L A Wise, K E Anderson, L Bernstein, I De Vivo, C M Friedenreich, S M Gapstur, R A Goldbohm, B Henderson, P L Horn-Ross, L Kolonel, J V Lacey, X Liang, J Lissowska, A Magliocco, M L McCullough, A B Miller, S H Olson, J R Palmer, Y Park, A V Patel, J Prescott, R Rastogi, K Robien, L Rosenberg, C Schairer, X Ou Shu, P A van den Brandt, R A Virkus, N Wentzensen, Y-B Xiang, W-H Xu, H P Yang and L A Brinton

Br J Cancer 2013 108: 727-734; advance online publication, January 24, 2013; 10.1038/bjc.2013.2

Book Review

Oncolytic viruses: methods and protocols

Kevin J Harrington

Br J Cancer 2013 108: 735; 10.1038/bjc.2012.571

Letters to the Editor

Benefits of screening cancer patients for distress still not demonstrated

J C Coyne

Br J Cancer 2013 108: 736-737; advance online publication, January 31, 2013; 10.1038/bjc.2013.16

Reply: benefits of screening cancer patients for distress still not demonstrated

L E Carlson, A Waller, S L Groff, L Zhong and B D Bultz

Br J Cancer 2013 108: 738-739; advance online publication, January 31, 2013; 10.1038/bjc.2013.17

A comment on ‘A morpho-molecular prognostic model for hepatocellular carcinoma’

I Halil Sahin and A Kaseb

Br J Cancer 2013 108: 740; 10.1038/bjc.2012.514

Reply: A morpho-molecular prognostic model for hepatocellular carcinoma

S Srivastava and M Salto-Tellez

Br J Cancer 2013 108: 741; 10.1038/bjc.2012.515

Comment on: ‘Second to fourth digit ratio (2D:4D), breast cancer risk factors, and breast cancer risk: a prospective cohort study’

L Costas, M Kogevinas and S de Sanjosé

Br J Cancer 2013 108: 742; advance online publication, November 27, 2012; 10.1038/bjc.2012.530

Reply to comment on: ‘Second to fourth digit ratio (2D:4D), breast cancer risk factors, and breast cancer risk: a prospective cohort study’

D C Muller, L Baglietto, J T Manning, C McLean, J L Hopper, D R English, G G Giles and G Severi

Br J Cancer 2013 108: 743; advance online publication, November 27, 2012; 10.1038/bjc.2012.531

Retraction

Aberrant methylation of SPARC in human lung cancers

M Suzuki, C Hao, T Takahashi, H Shigematsu, N Shivapurkar, U G Sathyanarayana, T Iizasa, T Fujisawa, K Hiroshima and A F Gazdar

Br J Cancer 2013 108: 744; 10.1038/bjc.2013.68